Influence of lifestyle and pharmacotherapy on hormonal and neural correlates of appetite in people living with overweight and obesity. (360G-Wellcome-319204_Z_24_Z)
A systematic review of functional magnetic resonance imaging (fMRI) studies examining neural responses to food cues after pharmacotherapy- or lifestyle- induced weight loss in individuals living with overweight or obesity will be conducted. The systematic review is registered on Prospero (ID: CRD42024526754). A lab-based study to investigate whether acute continuous walking influences appetite hormone levels, and whether exercise-induced changes in the hormones correlate with perceptions of appetite, nutritional intake and brain activity in individuals varying in weight status will be conducted. The appetite hormones include oxyntomodulin, GLP-1, ghrelin, leptin, PYY and glucose. Neural correlates to visual food cues will be assessed using blood-oxygen level dependent (BOLD) signals during fMRI scans of the brain. A third project will be a sub-study as part of a larger platform trial. This will include pre- and post-pharmacological intervention fMRI scan in participants randomised to receive the drug Tirzepatide, which is a dual GLP-1/GIP medication licensed in the UK for weight management and weight loss in people living with over weight or obesity.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.